CAMBRIDGE, Mass.--(BUSINESS WIRE)--Catabasis Pharmaceuticals, Inc., a clinical stage drug development company built on a pathway pharmacology technology platform, today announced that management will present an overview of Catabasis and its lead drug development programs at the following investor conferences in October:
- Leerink Partners Rare Diseases Roundtable on October 1, 2014, at Le Parker Meridien Hotel in New York. The Catabasis presentation will take place at 2:20pm ET.
- JMP Securities Life Sciences Private Company Conference on October 17, 2014, at Le Parker Meridien Hotel in New York.
Catabasis Pharmaceuticals is leveraging its pathway pharmacology drug development platform to bring important medicines to patients with severe lipid disorders and rare diseases. The Company’s mission is to address difficult-to-treat diseases through the simultaneous modulation of multiple targets in a disease pathway. For more information on our technology and pipeline of drug candidates, please visit www.catabasis.com.